AZ Centers Pearl As The Jewel Of Its Respiratory Franchise
This article was originally published in The Pink Sheet Daily
The British pharma announced its proposed acquisition of Pearl Therapeutics, adding a late-stage COPD drug to its pipeline and a triple combo therapy to its mid-stage pipeline.
You may also be interested in...
Keeping Track: Approvals For Nuplazid, Cabometyx, Bevespi And More; Digital Aripiprazole Tablet Needs More Study
The latest drug development news and highlights from our FDA Performance Tracker.
AstraZeneca's Hudson Optimistic On Return To Growth In 2017
US President Paul Hudson talked in an interview at the J.P. Morgan Healthcare conference about the company’s budding oncology portfolio, upcoming launches and growing optimism as the 2017 return-to-growth goal approaches.
Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal
Disappointing Phase III results have pushed AstraZeneca to end yet another partnership, leaving Rigel in a tough spot as the biotech considers how to move forward now that its largest partner has jumped ship.